Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2012; 18(2): 126-135
Published online Jan 14, 2012. doi: 10.3748/wjg.v18.i2.126
Published online Jan 14, 2012. doi: 10.3748/wjg.v18.i2.126
Figure 1 Suppression of esophageal cancer cell growth by curcumin, (-)-epigallocatechin-3-gallate, lovastatin and their combinations.
Esophageal cancer SKGT-4 and TE-8 cells were grown in monolayer overnight and then treated with or without curcumin (Cur) (40 μmol/L), (-)-epigallocatechin-3-gallate (EGCG) (40 μmol/L), lovastatin (L) (4 μmol/L) and their combinations for up to 5 d. Methyl thiazolyl tetrazolium assays were then carried out to detect changes in cell viability (see Methods section). The experiments were repeated three times and the results are summarized as a % of the control (Con) (mean ± SD) and analyzed statistically using the Student’s t test. aP < 0.05, bP < 0.01.
- Citation: Ye F, Zhang GH, Guan BX, Xu XC. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol 2012; 18(2): 126-135
- URL: https://www.wjgnet.com/1007-9327/full/v18/i2/126.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i2.126